Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.

Daniel, Dylan

Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. [electronic resource] - Blood Dec 2007 - 4037-46 p. digital

Publication Type: Journal Article

0006-4971

10.1182/blood-2007-02-076075 doi


Animals
Antibodies, Monoclonal--pharmacology
Antibodies, Monoclonal, Murine-Derived
Antibody Formation--drug effects
Antineoplastic Agents--agonists
Apoptosis--drug effects
Cell Line, Tumor
Complement System Proteins--metabolism
Drug Resistance, Neoplasm--drug effects
Drug Synergism
Female
Humans
Killer Cells, Natural--metabolism
Lymphocyte Depletion
Lymphoma, Non-Hodgkin--drug therapy
Mice
Mice, Inbred ICR
Mice, SCID
Receptors, TNF-Related Apoptosis-Inducing Ligand--antagonists & inhibitors
Receptors, Tumor Necrosis Factor--antagonists & inhibitors
Recombinant Proteins--agonists
Rituximab
TNF-Related Apoptosis-Inducing Ligand--agonists
Transplantation, Heterologous
Xenograft Model Antitumor Assays